Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma

References

• Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011;118: 3205–3211.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007;82:323–341.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64: 1546–1558.
   PubMedGoogle Scholar
• Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696–4700.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009;84:1095–1110.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21:529–534.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88: 226–235.
   PubMedGoogle Scholar
• Prochownik EV. c-Myc: linking transformation and genomic instability. Curr Mol Med 2008;8:446–458.
   PubMed Web of Science ®Google Scholar
• Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene 2008;27:6462–6472.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001;98:3082–3086.
   PubMed Web of Science ®Google Scholar
• Holien T, Sundan A. Oncogene addiction to c-MYC in myeloma cells. Oncotarget 2012;3:739–740.
   PubMedGoogle Scholar
• Tonon G. Molecular pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 2007;21:985–1006, vii.
   PubMed Web of Science ®Google Scholar
• Chiecchio L, Dagrada GP, Protheroe RK, et al. Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica 2009;94:1024–1028.
   PubMed Web of Science ®Google Scholar
• Chiecchio L, Dagrada GP, White HE, et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer 2009;48:624–636.
   PubMed Web of Science ®Google Scholar
• Fernandez de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013;27:780–791.
   PubMed Web of Science ®Google Scholar
• Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, et al. Plasmablastic lymphoma with MYC translocation:evidence for a common pathway in the generation of plasmablastic features. Mod Pathol 2010;23: 991–999.
   PubMed Web of Science ®Google Scholar
• Billecke L, Murga Penas EM, May AM, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol 2013;161:87–94.
   PubMed Web of Science ®Google Scholar
• Blade J, Fernandez de Larrea C, Rosinol L, et al. Soft-tissue plasmacytomas in multiple myeloma:incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011; 29:3805–3812.
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20: 1467–1473.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol 2005;130:662–670.
   PubMed Web of Science ®Google Scholar
• Delgado MD, Leon J. Myc roles in hematopoiesis and leukemia. Genes Cancer 2010;1:605–616.
   PubMedGoogle Scholar
• Palumbo A, Attal M, Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res 2011;17: 1253–1263.
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma:a randomised phase 3 study. Lancet 2010;376:2075–2085.
   PubMed Web of Science ®Google Scholar
• Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010;115:4168–4173.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Mateos MV, Gutierrez NC, et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013;121: 884–892.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma:the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489–3495.
   PubMed Web of Science ®Google Scholar
• Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012;119:940–948.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012;30:2946–2955.
   PubMed Web of Science ®Google Scholar